Ibrutinib (PCI-32765, Imbruvica), the first Food and Drug Administration (FDA)-approved covalent irreversible BTK inhibitor, has been used successfully for the treatment of patients with relapsed or refractory mantle-cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.